Diacylglycerol Lipase Alpha (DAGLα)

DAGLA Protein (Diacylglycerol Lipase Alpha)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Diacylglycerol Lipase Alpha (DAGLα)</th>
</tr>
<tr>
<td class="label">Regulatory Mechanism</td>
<td>Effect on DAGLA</td>
</tr>
<tr>
<td class="label">Calcium influx</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">Protein kinase A</td>
<td>Phosphorylation/inhibition</td>
</tr>
<tr>
<td class="label">Protein kinase C</td>
<td>Phosphorylation/activation</td>
</tr>
<tr>
<td class="label">Gq protein coupling</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">pH changes</td>
<td>pH-dependent activity</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">DO34</td>
<td>DAGLA activator</td>
</tr>
<tr>
<td class="label">JZL184</td>
<td>MAGL inhibitor</td>
</tr>
<tr>
<td class="label">THL</td>
<td>DAGLA inhibitor</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">CB1 Receptor</td>
<td>Endocannabinoid signaling</td>
</tr>
<tr>
<td class="label">CB2 Receptor</td>
<td>Immune modulation</td>
</tr>
<tr>
<td class="label">PLCβ</td>
<td>Lipid signaling</td>
</tr>
<tr>
<td class="label">MAGL</td>
<td>Endocannabinoid metabolism</td>
</tr>
<tr>
<td class="label">FAAH</td>
<td>Endocannabinoid metabolism</td>
</tr>
<tr>
<td class="label">GRP55</td>
<td>Potential rec

DAGLA Protein (Diacylglycerol Lipase Alpha)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Diacylglycerol Lipase Alpha (DAGLα)</th>
</tr>
<tr>
<td class="label">Regulatory Mechanism</td>
<td>Effect on DAGLA</td>
</tr>
<tr>
<td class="label">Calcium influx</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">Protein kinase A</td>
<td>Phosphorylation/inhibition</td>
</tr>
<tr>
<td class="label">Protein kinase C</td>
<td>Phosphorylation/activation</td>
</tr>
<tr>
<td class="label">Gq protein coupling</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">pH changes</td>
<td>pH-dependent activity</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">DO34</td>
<td>DAGLA activator</td>
</tr>
<tr>
<td class="label">JZL184</td>
<td>MAGL inhibitor</td>
</tr>
<tr>
<td class="label">THL</td>
<td>DAGLA inhibitor</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">CB1 Receptor</td>
<td>Endocannabinoid signaling</td>
</tr>
<tr>
<td class="label">CB2 Receptor</td>
<td>Immune modulation</td>
</tr>
<tr>
<td class="label">PLCβ</td>
<td>Lipid signaling</td>
</tr>
<tr>
<td class="label">MAGL</td>
<td>Endocannabinoid metabolism</td>
</tr>
<tr>
<td class="label">FAAH</td>
<td>Endocannabinoid metabolism</td>
</tr>
<tr>
<td class="label">GRP55</td>
<td>Potential receptor</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

DAGLA (Diacylglycerol Lipase Alpha), also known as DAGLα, is the primary biosynthetic enzyme for 2-arachidonoylglycerol (2-AG), the most abundant endocannabinoid in the mammalian brain[@bisogno2003][@zhang2018]. As a membrane-bound enzyme located primarily in the endoplasmic reticulum, DAGLA catalyzes the hydrolysis of diacylglycerol (DAG) to produce 2-AG, which then acts as a retrograde neurotransmitter at cannabinoid CB1 receptors throughout the central nervous system[@kano2009]. The enzyme plays critical roles in synaptic plasticity, neuroprotection, [inflammation](/entities/neuroinflammation) regulation, and has emerged as a significant target in understanding and treating [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurodegenerative conditions[@mulder2019][@zhang2017].

Protein Structure

Primary Structure

DAGLA is a large type I transmembrane protein consisting of 1048 amino acids with a molecular weight of approximately 120 kDa[@bisogno2003]. The protein exhibits several distinct structural domains that facilitate its enzymatic function and subcellular localization.

Domain Architecture

• N-terminal Signal Peptide:spans residues 1-40, targets the protein for secretion and membrane insertion
• Multiple Transmembrane Domains (1-6):spans residues 100-450 and anchors the protein to the endoplasmic reticulum membrane. These hydrophobic helices traverse the membrane multiple times, creating a characteristic serpentine topology[@himmelreich2021]
• Catalytic Lipase Domain:spans residues 500-800 and contains the active site for diacylglycerol hydrolysis. The catalytic triad (Ser-Asp-His) follows the canonical lipase motif[@chen2019]
• GXSXG Consensus Sequence: Located at residues 472-476, defines the active serine nucleophile
• C-terminal Regulatory Domain:spans residues 850-1048, modulates enzyme activity and subcellular localization

Structural Insights

X-ray crystallography and cryo-EM studies have revealed[@himmelreich2021][@chen2019]:

• The catalytic domain adopts a classic α/β hydrolase fold
• A lid domain covers the active site in the inactive conformation
• Conformational changes upon substrate binding activate the enzyme
• The transmembrane domains form a bundle that anchors to the ER membrane

Molecular Mechanisms

2-AG Biosynthesis Pathway

DAGLA operates within a coordinated biosynthetic cascade[@bisogno2003][@kano2009]:

Retrograde Synaptic Signaling

2-AG functions as a retrograde neurotransmitter with unique properties[@kano2009][@alger2011]:

• Postsynaptic Release: DAGLA is primarily postsynaptic, releasing 2-AG after depolarization
• Presynaptic Target: CB1 receptors on presynaptic terminals inhibit neurotransmitter release
• Temporal Dynamics: 2-AG signaling occurs over seconds to minutes
• Spatial Specificity: Restricted to active synaptic zones

Regulation of Enzyme Activity

Role in Neurodegeneration

Alzheimer's Disease

DAGLA and the 2-AG pathway have complex, multifaceted roles in [Alzheimer's disease](/diseases/alzheimers-disease)[@mulder2019][@bedse2017]:

Neuroprotective Effects

• 2-AG reduces [amyloid-beta](/proteins/amyloid-beta) toxicity in [neurons](/entities/neurons)
• CB1 receptor activation decreases [tau](/proteins/tau) phosphorylation
• Anti-inflammatory properties reduce microglial activation

• 2-AG regulates long-term depression (LTD)
• Impaired DAGLA function may contribute to synaptic loss
• Memory formation depends on endocannabinoid signaling

• DAGLA activators under investigation for AD treatment
• CB1 agonists show promise in preclinical models
• [Blood-brain barrier](/entities/blood-brain-barrier) penetration critical for drug development

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), DAGLA signaling is significantly altered[@zhang2017][@pagano2020]:

Dopaminergic Signaling Modulation

• 2-AG regulates dopamine release in the striatum
• Altered endocannabinoid tone in PD basal ganglia
• Potential for motor symptom modulation

• 2-AG has anti-inflammatory effects in the brain
• Microglial CB2 receptor activation reduces inflammation
• DAGLA expression altered in PD substantia nigra

• Endocannabinoid system hyperactivity contributes to dyskinesias
• DAGLA inhibition may reduce abnormal involuntary movements
• Therapeutic window for modulation[@martinez2019]

Multiple Sclerosis

The endocannabinoid system, including DAGLA, shows therapeutic relevance in [multiple sclerosis](/diseases/multiple-sclerosis)[@lora2018]:

• 2-AG levels elevated in MS lesions
• Anti-inflammatory effects in animal models
• Clinical trials of cannabinoid-based therapies ongoing

Stroke and Ischemia

DAGLA provides neuroprotection in stroke models[@zhang2019]:

• 2-AG reduces infarct size
• CB1 receptor activation provides neuroprotection
• Anti-excitotoxic effects mediated by DAGLA

Neuroinflammation

The anti-inflammatory properties of 2-AG are mediated through[@chiurchiu2018]:

• CB2 receptor on immune cells
• Inhibition of cytokine production
• Reduced microglial activation
• Promotion of regulatory T-cell function

Genetic Associations

DAGLA Polymorphisms

• rs2297563: Associated with cannabis dependence
• rs3762400: Modulates cognitive responses
• rs2228671: Missense variant with population-specific effects[@agrawal2018]

Expression Changes in Disease

• Decreased DAGLA expression in AD [hippocampus](/brain-regions/hippocampus)
• Altered DAGLA in PD substantia nigra
• Cell type-specific changes in neurodegeneration

Animal Models

Dagla Knockout Mice

• Complete knockout: Perinatal lethality in some backgrounds
• Conditional knockout: Viable with neurological phenotypes
• 2-AG deficiency: Severely reduced brain 2-AG levels
• Learning deficits: Impaired memory formation[@gao2010]

Transgenic Models

• DAGLA overexpression: Increased 2-AG, neuroprotection
• Conditional activation: Reversal of some deficits
• Disease models: Cross with AD/PD models shows protection[@tchantchou2021]

Pharmacological Studies

Therapeutic Targeting

DAGLA Activators

Small molecule activators of DAGLA are being developed for[@baggelaar2017][@hwang2020]:

• Neurodegenerative diseases: AD, PD, ALS
• Stroke and traumatic brain injury
• Mood disorders: Depression, anxiety
• Pain management: Chronic pain conditions

DAGLA Inhibitors

Inhibitors have research and therapeutic applications:

• JZL195: Dual DAGL/MAGL inhibitor
• KT-109: Selective DAGLA inhibitor
• Use in research: Probe 2-AG function

Challenges

• Blood-brain barrier penetration: Critical for CNS indications
• Peripheral vs. central selectivity: Avoid peripheral side effects
• Isoform specificity: DAGLA vs. DAGLB selectivity
• Therapeutic window: Balance efficacy and tolerability[@hwang2020]

Interactions

Protein-Protein Interactions

Metabolic Pathways

DAGLA sits at the intersection of multiple lipid signaling pathways[@bisogno2003]:

• Phosphoinositide signaling
• Diacylglycerol metabolism
• Arachidonic acid cascade
• Endocannabinoid biosynthesis

Expression Patterns

Brain Regional Distribution

• Cerebellum: Highest expression
• Hippocampus: High expression in CA1-CA3
• [Cortex](/brain-regions/cortex): Moderate expression
• Striatum: High expression in medium spiny neurons
• Brainstem: Variable expression

Cell Type Specificity

• Neurons: Primary cellular source
• [Astrocytes](/entities/astrocytes): Lower expression
• [Microglia](/cell-types/microglia-neuroinflammation): Inducible expression
• Oligodendrocytes: Under investigation

Biomarker Potential

As Diagnostic Marker

• Cerebrospinal fluid 2-AG levels under investigation
• Blood DAGLA activity as potential biomarker
• Correlates with disease stage

Disease Monitoring

• Treatment response to DAGLA modulators
• Disease progression markers
• Therapeutic window assessment

Future Directions

• Development of brain-penetrant DAGLA activators
• Understanding isoform-specific functions
• Clinical trials for neurodegenerative diseases
• Gene therapy approaches
• Combination with other therapeutic modalities

Related Pages

• [DAGLA Gene](/genes/dagla)
• [2-Arachidonoylglycerol (2-AG)](/entities/2-arachidonoylglycerol)
• [Endocannabinoid System](/entities/endocannabinoid-system)
• [CB1 Receptor](/entities/cb1-receptor)
• [MAGL Enzyme](/entities/magl-enzyme)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Synaptic Plasticity](/entities/synaptic-plasticity)

See Also

• [Alzheimer's disease](/diseases/alzheimers-disease)
• [Parkinson's disease](/diseases/parkinsons-disease)
• [multiple sclerosis](/diseases/multiple-sclerosis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References